Therapeutic potential of CDK8 inhibitor combined with sorafenib for hepatocellular carcinoma: mechanistic insights and in vitro validation
CDK8 is highly expressed in HCC tissues, suggesting its oncogenic role. Our in vitro findings demonstrate that the CDK8 inhibitor MSC2530818 synergizes with sorafenib to enhance anti-tumor efficacy against HCC cells, supporting further investigation of this combination strategy.
Authors
- Li Gao
- Su Du
- Hong Wu
- Zi-Li Lv
Institutions
- Qingdao University (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- Qingdao Municipal Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1186/s40001-025-03780-0
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00